Ana Acosta, MD
General Practice · Miami, FLNPI 1821406240
Payments from drug & device makers
What this record shows
12 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 51.9% of the total. Reporting peaked in 2024 at $1,019 and has fallen 98.4% since, to $16 in 2025. Among general practice clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $74.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Incyte Corporation$259
- Eisai Inc.$162
- AbbVie$149
- Pfizer$92
- Dexcom, Inc.$68
- plus $198 from 6 others
Across 1,294 payments — averaging $4866.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$2.9M
- E.r. Squibb & Sons, L.L.C.$962K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$495K
- Pfizer$434K
- Avanir Pharmaceuticals, Inc.$396K
- GSK$320K
- plus $790K from 11 others
What the payments were for
- Travel & lodging$83543%
- Food & beverage$1,09557%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 3 | $1,001 |
| Incyte Corporation | 3 | $259 |
| Eisai Inc. | 6 | $162 |
| AbbVie | 2 | $149 |
| Pfizer | 1 | $92 |
| Dexcom, Inc. | 1 | $68 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $65 |
| Boehringer Ingelheim | 2 | $42 |
| Amgen | 2 | $34 |
| Johnson & Johnson | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,930 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 13 | $14,356 |
| FenofibrateFenofibrate,micronized | 13 | $291 |
| Diclofenac Sodium | 13 | $252 |
| Pantoprazole Sodium | 21 | $113 |
| Amlodipine Besylate | 26 | $103 |
| Famotidine | 22 | $97 |
| Losartan Potassium | 29 | $91 |
| Pravastatin Sodium | 15 | $76 |
| Clonazepam | 13 | $50 |
| Levothyroxine Sodium | 11 | $46 |
| Tadalafil | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Other general practice in Miami
- Idalia AcostaMiami$99K
- Eddie GomezMiami$59K
- Aladino ValienteMiami$24K
- Viviana WaichMiami$20K
- Libia RiosMiami$15K
- Jose CardonaMiami$15K
- Rosa HuguetMiami$15K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.